Skip to main content

Table 1 The basic characteristics of the inclusion studies

From: ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis

First Author

Year

Country

Tumor stage

Regimen of chemotherapy

Genotyping method

Nunber of cases

Resistant

Responder

P (HWE)

NOS score

CC

CT

TT

CC

CT

TT

Kang

2006

Korean

I-IV

platinum-based chemotherapy

Snapshot

60

15

5

0

20

16

4

0.763

8

Smith

2007

USA

I-IV

platium ± paditaxel chemotherapy

PCR–RFLP

176

11

22

15

23

60

45

0.701

8

Steffensen

2008

Danish

II-IV

carboplatin and cyclophosphamide combined-chemotherapy

TaqMan assay-based Real time PCR

100

3

7

2

12

34

42

0.239

8

Steffensen

2011

Danish

I-IV

Combined with carboplatin and paclitaxel

PCR–RFLP

157

2

4

7

15

71

58

0.321

8

Bösmüller

2011

Germany

I-III

Standard carboplatin-taxane

PCR–RFLP

41

6

5

3

7

9

11

0.098

8

Moxley

2013

USA

IIIB-IV

Platium- Based Chemotherapy

PCR–RFLP

64

10

13

9

14

8

10

0.005

8

Qi BL

2013

China

I-IV

Platinum-based combination

Snapshot

220

38

26

9

78

67

2

0.003

7

Huo XY

2017

China

I-IV

TP (paclitaxel / docetaxel + cisplatin / carboplatin / oxaliplatin)

PCR–RFLP

280

43

29

16

104

82

6

0.049

7

Yang SY

2017

China

III-IV

Cisplatin / carboplatin, combined with cyclophosphamide / paclitaxel

PCR–RFLP

209

28

31

12

70

67

1

0.000

7

Bao Y

2020

China

II-IV

cisplatin based Chemotherapy

PCR–RFLP

559

209

124

47

115

55

9

0.473

8

  1. NOS Newcastle–Ottawa Scale, PCR–RFLP Polymerase chain reaction-restriction fragment length polymorphism, HWE Hardy–Weinberg equilibrium